{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:34:02Z","timestamp":1786988042500,"version":"build-2736575974"},"reference-count":134,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2005,2]]},"DOI":"10.1016\/j.ejim.2004.10.007","type":"journal-article","created":{"date-parts":[[2005,2,23]],"date-time":"2005-02-23T07:14:19Z","timestamp":1109142859000},"page":"3-11","source":"Crossref","is-referenced-by-count":18,"title":["The aldosterone antagonist and facultative diuretic eplerenone: a critical review"],"prefix":"10.1016","volume":"16","author":[{"given":"Ariel J.","family":"Reyes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rio F.C.","family":"Maranh\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Hern\u00e1ndez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2004.10.007_bib1","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1345\/aph.1C027","article-title":"Eplerenone\u2014a novel selective aldosterone blocker","volume":"36","author":"Zillich","year":"2002","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejim.2004.10.007_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","article-title":"Efficacy of eplerenone added to renin\u2013angiotensin blockade in hypertensive patients","volume":"40","author":"Krum","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2004.10.007_bib3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ejim.2004.10.007_bib4","series-title":"Diuretics IV: chemistry, pharmacology and clinical applications","first-page":"391","article-title":"The antialdosterone substance spironolactone is a facultative natriuretic, antikaliuretic and antimagnesiuretic in man","author":"Leary","year":"1993"},{"key":"10.1016\/j.ejim.2004.10.007_bib5","series-title":"Magnesium 1993","first-page":"299","article-title":"Spironolactone is a facultative diuretic and antimagnesiuretic in man","author":"Leary","year":"1994"},{"key":"10.1016\/j.ejim.2004.10.007_bib6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00004872-200103000-00001","article-title":"A review of the medical treatment of primary aldosteronism","volume":"19","author":"Lim","year":"2001","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejim.2004.10.007_bib7","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1210\/en.2003-0279","article-title":"Minireview: primary aldosteronism-changing concepts in diagnosis and treatment","volume":"144","author":"Young","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejim.2004.10.007_bib8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1258\/000456303322326362","article-title":"Primary hyperaldosteronism","volume":"40","author":"Nadar","year":"2003","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.ejim.2004.10.007_bib9","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1097\/00004872-200311000-00025","article-title":"High rate of detection of primary aldosteronism, including surgically treatable forms, after \u2018non-selective\u2019 screening of hypertensive patients","volume":"21","author":"Stowasser","year":"2003","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejim.2004.10.007_bib10","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","article-title":"Hyperaldosteronism between Black and White subjects with resistant hypertension","volume":"40","author":"Calhoun","year":"2002","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejim.2004.10.007_bib11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0895-7061(01)02342-1","article-title":"The role of spironolactone in the treatment of patients with refractory hypertension","volume":"15","author":"Ouzan","year":"2002","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ejim.2004.10.007_bib12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/sj.jhh.1001320","article-title":"Is aldosterone the missing link in refractory hypertension?: aldosterone-to-renin ratio as a marker of inappropriate aldosterone activity","volume":"16","author":"Lim","year":"2002","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ejim.2004.10.007_bib13","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1046\/j.1365-2125.1999.00070.x","article-title":"Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study","volume":"48","author":"Lim","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejim.2004.10.007_bib14","first-page":"394","article-title":"The aldosterone\/renin ratio as a screening test for primary aldosteronism","volume":"90","author":"Rayner","year":"2000","journal-title":"S. Afr. Med. J."},{"key":"10.1016\/j.ejim.2004.10.007_bib15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00000441-200210000-00010","article-title":"Hyperaldosteronism: the internist's hypertensive disease","volume":"324","author":"Brown","year":"2002","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.ejim.2004.10.007_bib16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00041552-200303000-00005","article-title":"Aldo is back: recent advances and unresolved controversies in hyperaldosteronism","volume":"12","author":"Auchus","year":"2003","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"Suppl. A","key":"10.1016\/j.ejim.2004.10.007_bib17","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/S1096-6374(03)00064-9","article-title":"Primary aldosteronism-treatment options","volume":"13","author":"Young","year":"2003","journal-title":"Growth Horm. IGF Res."},{"key":"10.1016\/j.ejim.2004.10.007_bib18","first-page":"381","article-title":"Reassessing the role of spironolactone in hypertension","volume":"3","author":"Materson","year":"1986","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejim.2004.10.007_bib19","first-page":"568","article-title":"Spironolactone in the treatment of hypertension: a review","volume":"8","author":"Brest","year":"1986","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejim.2004.10.007_bib20","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","article-title":"Efficacy and tolerance of spironolactone in essential hypertension","volume":"60","author":"Jeunemaitre","year":"1987","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejim.2004.10.007_bib21","doi-asserted-by":"crossref","first-page":"24A","DOI":"10.1016\/S0895-7061(02)02334-8","article-title":"Comparison of eplerenone and losartan in patients with low-renin hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ejim.2004.10.007_bib22","doi-asserted-by":"crossref","first-page":"24A","DOI":"10.1016\/S0895-7061(02)02333-6","article-title":"Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone\/enalapril combination therapy in diabetic hypertensives with microalbuminuria","volume":"15","author":"Epstein","year":"2002","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ejim.2004.10.007_bib23","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","article-title":"Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients","volume":"41","author":"Flack","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejim.2004.10.007_bib24","first-page":"38","article-title":"Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension","volume":"92","author":"White","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2004.10.007_bib25","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2004.10.007_bib26","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1001\/archinte.163.13.1543","article-title":"Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension","volume":"163","author":"Hollenberg","year":"2003","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ejim.2004.10.007_bib27","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/S0149-2918(03)80282-5","article-title":"Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension","volume":"25","author":"Burgess","year":"2003","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejim.2004.10.007_bib28","unstructured":"Inspra (eplerenone USA approved prescribing information, October 2003) [11 screens]. Available from URL: http:\/\/www.pfizer.com\/download\/uspi_inspra.pdf. Accessed on the 26 October, 2003."},{"key":"10.1016\/j.ejim.2004.10.007_bib29","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2004.10.007_bib30","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jama.1997.03540330061036","article-title":"Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis","volume":"277","author":"Psaty","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2004.10.007_bib31","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/sj.jhh.1000436","article-title":"Metabolic and orthostatic blood pressure responses to a low-sodium diet in elderly hypertensives","volume":"11","author":"Fotherby","year":"1997","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ejim.2004.10.007_bib32","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11906-002-0011-8","article-title":"Resistant hypertension","volume":"4","author":"Calhoun","year":"2002","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.ejim.2004.10.007_bib33","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am. J. Hypertens."},{"issue":"Suppl. 2","key":"10.1016\/j.ejim.2004.10.007_bib34","first-page":"S25","article-title":"Ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design","volume":"11","author":"Breitstadt","year":"1993","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejim.2004.10.007_bib35","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/archinte.1996.00440030072009","article-title":"Losartan and low-dose hydrochlorothiazide in patients with essential hypertension","volume":"156","author":"MacKay","year":"1996","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ejim.2004.10.007_bib36","first-page":"208","article-title":"Low-dose chlorthalidone treatment in previously untreated hypertension","volume":"29","author":"Korduner","year":"1981","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/j.ejim.2004.10.007_bib37","first-page":"465","article-title":"Multicentre randomized cross-over double-blind comparison between chlorthalidone and slow-release oxprenolol in mild-to-moderate hypertension","volume":"35","author":"Pollavini","year":"1984","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/j.ejim.2004.10.007_bib38","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1136\/bmj.300.6730.975","article-title":"Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects","volume":"300","author":"Carlsen","year":"1990","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2004.10.007_bib39","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/00004872-199816070-00020","article-title":"A randomized comparison of a conventional dose, a low dose and alternate-day dosing of bendrofluazide in hypertensive patients","volume":"16","author":"Girvin","year":"1998","journal-title":"J. Hypertens."},{"issue":"Suppl. 1","key":"10.1016\/j.ejim.2004.10.007_bib40","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1038\/sj.jhh.1001349","article-title":"Diuretics in the therapy of hypertension","volume":"16","author":"Reyes","year":"2002","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ejim.2004.10.007_bib41","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/bmj.1.6158.224","article-title":"Comparison of natriuretic, uricosuric, and antihypertensive properties of tienilic acid, bendrofluazide, and spironolactone","volume":"1","author":"Roberts","year":"1979","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejim.2004.10.007_bib42","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/0002-9149(88)90551-6","article-title":"Long-term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents for treatment of essential hypertension","volume":"62","author":"Jeunemaitre","year":"1988","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejim.2004.10.007_bib43","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1161\/01.HYP.35.5.1025","article-title":"Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program","volume":"35","author":"Franse","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2004.10.007_bib44","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1056\/NEJM199406303302603","article-title":"Diuretic therapy for hypertension and the risk of primary cardiac arrest","volume":"330","author":"Siscovick","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejim.2004.10.007_bib45","first-page":"1539","article-title":"Non-potassium-sparing diuretics and risk of sudden cardiac death","volume":"13","author":"Grobbee","year":"1995","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejim.2004.10.007_bib46","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1006\/jmcc.1999.0963","article-title":"Extra-adrenal mineralocorticoids and cardiovascular tissue","volume":"3","author":"Slight","year":"1999","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ejim.2004.10.007_bib47","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s000590050024","article-title":"Aldosterone and myocardial fibrosis in heart failure","volume":"25","author":"Brilla","year":"2000","journal-title":"Herz"},{"key":"10.1016\/j.ejim.2004.10.007_bib48","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1006\/jmcc.2000.1129","article-title":"Induction of cardiac fibrosis by aldosterone","volume":"32","author":"Lijnen","year":"2000","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ejim.2004.10.007_bib49","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/00004872-200208000-00002","article-title":"Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system","volume":"20","author":"Young","year":"2002","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejim.2004.10.007_bib50","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1161\/01.HYP.0000034738.79310.06","article-title":"Spironolactone improves angiotensin-induced vascular changes and oxidative stress","volume":"40","author":"Virdis","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2004.10.007_bib51","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1046\/j.1440-1681.2003.03906.x","article-title":"Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats","volume":"30","author":"Mill","year":"2003","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.ejim.2004.10.007_bib52","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1161\/01.CIR.0000039328.33137.6C","article-title":"Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone","volume":"106","author":"Lacolley","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2004.10.007_bib53","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/hyp.39.2.614","article-title":"Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading","volume":"39","author":"Martinez","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2004.10.007_bib54","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1749-6632.2002.tb04415.x","article-title":"The pathophysiology of aldosterone in the cardiovascular system","volume":"970","author":"Rocha","year":"2002","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.ejim.2004.10.007_bib55","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1161\/01.CIR.0000051865.66123.B7","article-title":"Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms","volume":"107","author":"Hein","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2004.10.007_bib56","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/01.HYP.0000036399.80194.D8","article-title":"Aldosterone antagonist improves diastolic function in essential hypertension","volume":"40","author":"Grandi","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2004.10.007_bib57","first-page":"33","article-title":"Diuretic therapy of hypertension in the United States: low-dose becomes lower","volume":"10\/3","author":"Materson","year":"1995","journal-title":"Prog. Pharmacol. Clin. Pharmacol."},{"key":"10.1016\/j.ejim.2004.10.007_bib58","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1071-9164(96)80009-1","article-title":"Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure","volume":"2","author":"Struthers","year":"1996","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ejim.2004.10.007_bib59","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s11906-003-0087-9","article-title":"RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease","volume":"5","author":"Lakkis","year":"2003","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.ejim.2004.10.007_bib60","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1161\/01.CIR.0000030935.89559.04","article-title":"Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure","volume":"106","author":"Jorde","year":"2002","journal-title":"Circulation"},{"issue":"Suppl. 1","key":"10.1016\/j.ejim.2004.10.007_bib61","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1038\/sj.jhh.1001354","article-title":"Diuretics in the treatment of patients who present congestive heart failure and hypertension","volume":"16","author":"Reyes","year":"2002","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ejim.2004.10.007_bib62","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejim.2004.10.007_bib63","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0735-1097(02)01965-4","article-title":"Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure","volume":"40","author":"Cicoira","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejim.2004.10.007_bib64","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/S0735-1097(02)02382-3","article-title":"Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy","volume":"40","author":"Rousseau","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejim.2004.10.007_bib65","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0735-1097(03)00765-4","article-title":"Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD)","volume":"42","author":"Domanski","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejim.2004.10.007_bib66","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/hy1101.099484","article-title":"Treatment of congestive heart failure: interfering the aldosterone\u2013cardiac extracellular matrix relationship","volume":"38","author":"Zannad","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2004.10.007_bib67","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1210\/en.2002-220120","article-title":"Selective aldosterone blockade prevents angiotensin II\/salt-induced vascular inflammation in the rat heart","volume":"143","author":"Rocha","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejim.2004.10.007_bib68","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am. J. Physiol., Heart Circ. Physiol."},{"key":"10.1016\/j.ejim.2004.10.007_bib69","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/hy0302.105295","article-title":"Aldosterone and d-glucose stimulate the proliferation of human cardiac myofibroblasts in vivo","volume":"39","author":"Neumann","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2004.10.007_bib70","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1161\/01.CIR.0000068340.96506.0F","volume":"107","author":"Hayashi","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2004.10.007_bib71","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1210\/en.2002-220956","article-title":"Aldosterone inhibits inducible nitric oxide synthase in neonatal rat cardiomyocytes","volume":"144","author":"Chun","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejim.2004.10.007_bib72","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0008-6363(03)00251-7","article-title":"Aldosterone-receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure","volume":"58","author":"Cittadini","year":"2003","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejim.2004.10.007_bib73","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0895-7061(02)03268-5","article-title":"Prevention of high salt diet-induced cardiac hypertrophy and fibrosis by spironolactone","volume":"16","author":"Lal","year":"2003","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ejim.2004.10.007_bib74","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/01.RES.0000080521.15238.E5","article-title":"Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure","volume":"93","author":"Qin","year":"2003","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejim.2004.10.007_bib75","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2003.05.003","article-title":"Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone-receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction","volume":"42","author":"Fraccarollo","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejim.2004.10.007_bib76","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1055\/s-0037-1613404","article-title":"Inhibition of platelet activation in congestive heart failure by aldosterone-receptor antagonism and ACE inhibition","volume":"89","author":"Schafer","year":"2003","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejim.2004.10.007_bib77","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0008-6363(03)00333-X","article-title":"Addition of the selective aldosterone-receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction","volume":"58","author":"Schafer","year":"2003","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejim.2004.10.007_bib78","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/00005344-200306000-00019","article-title":"Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein e-deficient mice","volume":"41","author":"Keidar","year":"2003","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejim.2004.10.007_bib79","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0735-1097(02)02855-3","article-title":"Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy","volume":"41","author":"Kasama","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejim.2004.10.007_bib80","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1006\/jmcc.2002.2088","article-title":"Molecular mechanisms of myocardial remodeling. The role of aldosterone","volume":"34","author":"Delcayre","year":"2002","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ejim.2004.10.007_bib81","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1358\/mf.2003.25.7.778094","article-title":"Role of intracardiac renin\u2013angiotensin\u2013aldosterone system in extracellular matrix remodeling","volume":"25","author":"Lijnen","year":"2003","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"10.1016\/j.ejim.2004.10.007_bib82","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1210\/jc.86.11.5121","article-title":"Cardiac steroidogenesis in the normal and failing heart","volume":"86","author":"Young","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejim.2004.10.007_bib83","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1046\/j.1440-1681.2003.03867.x","article-title":"Extra-adrenal production of corticosteroids","volume":"30","author":"Davies","year":"2003","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"Suppl. 1","key":"10.1016\/j.ejim.2004.10.007_bib84","first-page":"S19","article-title":"Transcardiac gradient of aldosterone before and after spironolactone in patients with congestive heart failure","volume":"41","author":"Tsutamoto","year":"2003","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejim.2004.10.007_bib85","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejim.2004.10.007_bib86","first-page":"619","article-title":"Therapy with diuretics in hepatic disease with edema and management of refractory ascites","volume":"9","author":"Arroyo","year":"1992","journal-title":"Prog. Pharmacol. Clin. Pharmacol."},{"key":"10.1016\/j.ejim.2004.10.007_bib87","first-page":"183","article-title":"Pathogenesis of ascites and renal salt retention in cirrhosis","volume":"47","author":"Palmer","year":"1999","journal-title":"J. Investig. Med."},{"key":"10.1016\/j.ejim.2004.10.007_bib88","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/jhep.2003.50315","article-title":"The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club","volume":"38","author":"Moore","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2004.10.007_bib89","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","article-title":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])","volume":"78","year":"1996","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejim.2004.10.007_bib90","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/S0140-6736(05)72606-4","article-title":"Spironolactone and congestive heart failure","volume":"355","author":"Georges","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2004.10.007_bib91","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0002-9343(01)00642-8","article-title":"Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases","volume":"110","author":"Schepkens","year":"2001","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejim.2004.10.007_bib92","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00000539-200207000-00006","article-title":"Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency","volume":"95","author":"Hu","year":"2002","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.ejim.2004.10.007_bib93","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3109\/00048677909159130","article-title":"Mental symptoms and electrolyte imbalance","volume":"13","author":"Taylor","year":"1979","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.ejim.2004.10.007_bib94","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1001\/jama.1978.03290140058027","article-title":"Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment","volume":"240","author":"Feinfeld","year":"1978","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2004.10.007_bib95","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1136\/pgmj.69.817.887","article-title":"Type IV renal tubular acidosis and spironolactone therapy in the elderly","volume":"69","author":"O'Connell","year":"1993","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.ejim.2004.10.007_bib96","series-title":"The regulation of potassium balance","first-page":"207","article-title":"Clinical expression of potassium disturbances","author":"Knochel","year":"1989"},{"key":"10.1016\/j.ejim.2004.10.007_bib97","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0950-351X(89)80013-8","article-title":"Hyponatremia","volume":"3","author":"Verbalis","year":"1989","journal-title":"Bailli\u00e8re's Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejim.2004.10.007_bib98","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/pgmj.56.654.254","article-title":"Hyperkalaemic paralysis due to spironolactone","volume":"56","author":"Udezue","year":"1980","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.ejim.2004.10.007_bib99","first-page":"339","article-title":"Successful treatment of hyperkalemic quadriplegia associated with spironolactone","volume":"26","author":"Rado","year":"1988","journal-title":"Int. J. Clin. Pharmacol. Ther. Toxicol."},{"key":"10.1016\/j.ejim.2004.10.007_bib100","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1378\/chest.63.6.1023","article-title":"Hyperkalemic cardiac arrhythmia secondary to spironolactone","volume":"63","author":"Pongpaew","year":"1973","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2004.10.007_bib101","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1001\/jama.1976.03270250043025","article-title":"Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia","volume":"236","author":"Yap","year":"1976","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2004.10.007_bib102","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/00004872-200107000-00018","article-title":"High and low serum potassium associated with cardiovascular events in diuretic-treated patients","volume":"19","author":"Cohen","year":"2001","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejim.2004.10.007_bib103","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(87)91340-7","article-title":"Spironolactone and hyperkalaemia in patients with impaired renal failure","volume":"2","author":"McGeown","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2004.10.007_bib104","doi-asserted-by":"crossref","first-page":"917","DOI":"10.7326\/0003-4819-138-11-200306030-00013","article-title":"Pharmacotherapy for heart failure in patients with renal insufficiency","volume":"138","author":"Shlipak","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejim.2004.10.007_bib105","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0002-9149(02)02581-X","article-title":"Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease","volume":"90","author":"Obialo","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejim.2004.10.007_bib106","first-page":"147","article-title":"Spironolactone-associated aggravation of renal functional impairment","volume":"83","author":"Neale","year":"1976","journal-title":"N. Z. Med. J."},{"key":"10.1016\/j.ejim.2004.10.007_bib107","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1365-2710.2003.00491.x","article-title":"The safety of spironolactone treatment in patients with heart failure","volume":"28","author":"Anton","year":"2003","journal-title":"J. Clin. Pharm. Ther."},{"issue":"Suppl. 1","key":"10.1016\/j.ejim.2004.10.007_bib108","first-page":"S81","article-title":"Potential adverse effects of antihypertensive drugs in the elderly","volume":"6","author":"Lamy","year":"1988","journal-title":"J. Hypertens."},{"issue":"Suppl. 8","key":"10.1016\/j.ejim.2004.10.007_bib109","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1097\/00005344-198812081-00010","article-title":"Clinical care of the aging hypertensive patient","volume":"12","author":"Tuck","year":"1988","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejim.2004.10.007_bib110","doi-asserted-by":"crossref","first-page":"25H","DOI":"10.1016\/0002-9149(89)90112-4","article-title":"Hypertension in the aged: a pathophysiologic basis for treatment","volume":"63","author":"Weber","year":"1989","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejim.2004.10.007_bib111","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00005792-198511000-00001","article-title":"Drug-induced hyperkalemia","volume":"64","author":"Ponce","year":"1985","journal-title":"Medicine"},{"key":"10.1016\/j.ejim.2004.10.007_bib112","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00045391-199803000-00013","article-title":"University of Miami Division of Clinical Pharmacology therapeutic rounds: drug-induced hyperkalemia","volume":"5","author":"Preston","year":"1998","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.ejim.2004.10.007_bib113","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/bmj.326.7379.35","article-title":"Danger of salt substitutes that contain potassium in patients with renal failure","volume":"326","author":"Doorenbos","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2004.10.007_bib114","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/00042737-199710000-00014","article-title":"Hyperkalaemia and diarrhoea in a patient with surreptitious ingestion of potassium sparing diuretics","volume":"9","author":"Stepan","year":"1997","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejim.2004.10.007_bib115","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1136\/heart.85.4.e8","article-title":"Serious adverse events experienced by patients with chronic heart failure taking spironolactone","volume":"85","author":"Berry","year":"2001","journal-title":"Heart"},{"key":"10.1016\/j.ejim.2004.10.007_bib116","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1093\/ndt\/gfg295","article-title":"Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone","volume":"18","author":"Cruz","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejim.2004.10.007_bib117","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/bmj.327.7407.147","article-title":"Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases","volume":"327","author":"Wrenger","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2004.10.007_bib118","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1067\/mlc.2000.110371","article-title":"Acid\u2013base and endocrine effects of aldosterone and angiotensin II inhibition in metabolic acidosis in human patients","volume":"136","author":"Henger","year":"2000","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.ejim.2004.10.007_bib119","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.2174\/1381612003398717","article-title":"COX-2 and the kidneys","volume":"6","author":"Stichtenoth","year":"2000","journal-title":"Curr. Pharm. Des."},{"issue":"6A","key":"10.1016\/j.ejim.2004.10.007_bib120","doi-asserted-by":"crossref","first-page":"10D","DOI":"10.1016\/S0002-9149(02)02232-4","article-title":"Cyclooxygenase-2 inhibition and renal physiology","volume":"89","author":"Harris","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejim.2004.10.007_bib121","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1067\/mcp.2002.126182","article-title":"Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet","volume":"72","author":"Schwartz","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejim.2004.10.007_bib122","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0735-1097(02)02694-3","article-title":"Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines","volume":"41","author":"Bozkurt","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejim.2004.10.007_bib123","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1136\/bmj.327.7424.1141","article-title":"Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study","volume":"327","author":"Svensson","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2004.10.007_bib124","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1001\/archinte.1974.00320210082011","article-title":"An effect of spironolactone on urinary acidification in normal man","volume":"134","author":"Manuel","year":"1974","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ejim.2004.10.007_bib125","first-page":"F381","article-title":"Renal and systemic acid\u2013base effects of chronic spironolactone administration","volume":"240","author":"Hulter","year":"1981","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejim.2004.10.007_bib126","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00002512-199711010-00004","article-title":"Drug-induced syndrome of inappropriate antidiuretic hormone secretion. Causes, diagnosis and management","volume":"11","author":"Chan","year":"1997","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ejim.2004.10.007_bib127","first-page":"206","article-title":"Inappropriate antidiuretic hormone secretion","volume":"6","author":"Miller","year":"1997","journal-title":"Curr. Ther. Endocrinol. Metab."},{"key":"10.1016\/j.ejim.2004.10.007_bib128","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1159\/000188036","article-title":"Spironolactone\u2013associated hyponatremic coma","volume":"67","author":"Hirschl","year":"1994","journal-title":"Nephron"},{"issue":"Suppl. 1","key":"10.1016\/j.ejim.2004.10.007_bib129","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1600-0773.1984.tb03643.x","article-title":"Hyponatremia in congestive heart failure treated with diuretics","volume":"54","author":"Orinius","year":"1984","journal-title":"Acta Pharm. Toxicol."},{"key":"10.1016\/j.ejim.2004.10.007_bib130","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00877956","article-title":"Renal excretory responses to single and repeated administration of diuretics in healthy subjects. Clinical connotations","volume":"7","author":"Reyes","year":"1993","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ejim.2004.10.007_bib131","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1159\/000013496","article-title":"Diuretic-induced hyponatremia","volume":"19","author":"Spital","year":"1999","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.ejim.2004.10.007_bib132","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/archinte.1986.00360190131018","article-title":"Severe diuretic-induced hyponatremia in the elderly","volume":"146","author":"Ashouri","year":"1986","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ejim.2004.10.007_bib133","series-title":"Diuretics IV: chemistry, pharmacology and clinical applications","first-page":"3","article-title":"Thiazide-induced hyponatremia","author":"Fernandez","year":"1993"},{"key":"10.1016\/j.ejim.2004.10.007_bib134","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0022-2143(03)00062-3","article-title":"Aldosteronism revisited: perspectives on less well-recognized actions of aldosterone","volume":"14","author":"Weber","year":"2003","journal-title":"J. Lab. Clin. Med."}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620504002730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620504002730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T12:53:17Z","timestamp":1706014397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620504002730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":134,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["S0953620504002730"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2004.10.007","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2005,2]]}}}